Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that a topical compounded formulation may improve hair density and general appearance in male patients with androgenetic alopecia after 6 months of use.

This study found that the HPCH-based formulation P-08–016 may facilitate finasteride deposition in the dermis, potentially offering an alternative to systemic therapy by minimizing systemic absorption.

This study validated the differential stripping technique on hairless rat skin and found that the P-08–016 formulation delivered more finasteride to the epidermis and appendages compared to P-10–008.

Topical finasteride may better target hair follicles without significant benefits over oral form.

This study described the development and evaluation of a finasteride nanogel for treating androgenetic alopecia, reporting higher cumulative drug release and enhanced spreadability compared to a plain gel, suggesting potential as a treatment option.

This study evaluated Finasteride-loaded nanostructured lipid carriers for topical use in treating androgenetic alopecia and found that these carriers offer sustained drug release and may reduce systemic side effects compared to oral administration.

This study found that the MorrF topical solution combination showed significantly better hair growth improvements than Minoxidil alone in male patients with Androgenetic Alopecia.

In a study using human scalp skin grafts on SCID mice, topical flutamide and finasteride significantly improved hair growth in male-pattern baldness compared to placebo, with flutamide showing superior results to finasteride.

In this study, researchers reviewed literature on topical delivery of finasteride for androgenetic alopecia, finding that liposomal gels with specific additives showed the highest skin permeation rates, suggesting potential for reducing systemic side effects compared to oral formulations.

This study developed a stable lyophilized finasteride nanosystem for topical delivery and found that it was stable for 90 days and that formulations with 15% trehalose showed favorable characteristics for potential use in treating androgenic alopecia.

This study developed and validated a precise and rapid HPLC method to simultaneously determine Minoxidil and Finasteride in pharmaceuticals, demonstrating successful application for routine quality control without interference from excipients.

A new topical finasteride formulation effectively promotes hair growth with fewer side effects.

This study found that using gallate-containing formulations like EGCG or tannic acid increased the solubility and controlled release of finasteride in microspheres, enhancing its dermal penetration in pig skin by 10 to 50 times compared to a control.

This study found that a finasteride topical gel formulation using propylene glycol and Tween® 80 showed significantly enhanced permeation compared to a control formulation without these enhancers.

In this study, researchers developed a polyherbal serum using extracts from various herbs and tested it on rats with testosterone-induced alopecia, observing it potentially promotes hair growth and decreases androgen-induced hair loss, with results compared to a positive control using finasteride.

This review discusses current topical treatments, natural products, and complementary therapies for androgenetic alopecia, but it reports no new clinical results.

In this survey, dermatologists in India reported preferring alcohol-free minoxidil combined with procapil and finasteride over traditional alcohol-based formulations for managing androgenetic alopecia, citing better tolerance and patient adherence.

This study aims to develop three topical formulations of finasteride to reduce its side effects for treating androgenic alopecia.

This article provides an overview of current treatments and alternative formulations for androgenic alopecia but reports no new clinical results.

This study found that polymeric nanoparticles may effectively deliver finasteride topically to hair follicles, potentially improving alopecia treatment with fewer side effects than oral forms.

This study suggests that the developed PBPK model effectively predicts pharmacokinetic and pharmacodynamic profiles of topical finasteride and minoxidil on the scalp, indicating potential broader applicability for other formulations.

In this study, researchers developed a new topical atraric acid formulation, AA-TF#15, which showed a significantly higher drug penetration and increased hair regrowth in mice compared to minoxidil and finasteride treatments, suggesting its potential effectiveness for treating scalp androgenic alopecia.

This study found that topical finasteride was absorbed into the bloodstream to a minimal extent in male rats, even with repeated applications, suggesting low systemic exposure.

This study found that using hollow mesoporous silica nanoparticles as carriers in a topical finasteride formulation significantly enhanced drug retention and hair regrowth in an AGA mouse model, suggesting a promising approach for treating androgenetic alopecia with reduced side effects.

This study found that finasteride-loaded liposomal formulations achieved significantly higher skin permeation and deposition compared to conventional gels and solutions, suggesting potential for effective topical application.

In this study, researchers developed a novel gel formulation combining zinc oxide nanoparticles and finasteride-loaded nanostructured lipid carriers, which showed promising results for topical delivery and effective skin penetration, potentially offering a new treatment approach for androgenic alopecia.

This study found that both topical and oral finasteride significantly reduced plasma DHT after one week, with lower finasteride plasma exposure for the topical formulation.

In this narrative review, researchers reported that oral finasteride significantly improved hair count and density in male androgenetic alopecia but had higher systemic exposure and potential side effects compared to topical formulations, which provided similar efficacy with lower systemic DHT suppression.

This study found that a nanostructured lipid carrier gel containing Minoxidil and Finasteride met desired criteria for stability and performance, suggesting it may be an effective topical treatment for hair loss, especially in extreme conditions.